CL2011002209A1 - Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. - Google Patents

Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.

Info

Publication number
CL2011002209A1
CL2011002209A1 CL2011002209A CL2011002209A CL2011002209A1 CL 2011002209 A1 CL2011002209 A1 CL 2011002209A1 CL 2011002209 A CL2011002209 A CL 2011002209A CL 2011002209 A CL2011002209 A CL 2011002209A CL 2011002209 A1 CL2011002209 A1 CL 2011002209A1
Authority
CL
Chile
Prior art keywords
urinary incontinence
mercaptoquinoline
epilepsy
carboxamide
anxiety
Prior art date
Application number
CL2011002209A
Other languages
English (en)
Inventor
Sven Kuhnert
Gregor Kless Achim Schroder Wolfgang Bahrenberg
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002209(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CL2011002209A1 publication Critical patent/CL2011002209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Abstract

Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, entre otras enfermedades.
CL2011002209A 2009-03-12 2011-09-08 Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria. CL2011002209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09003597 2009-03-12

Publications (1)

Publication Number Publication Date
CL2011002209A1 true CL2011002209A1 (es) 2012-02-10

Family

ID=40671387

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002209A CL2011002209A1 (es) 2009-03-12 2011-09-08 Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.

Country Status (20)

Country Link
US (2) US20100234372A1 (es)
EP (1) EP2406229A1 (es)
JP (1) JP5727946B2 (es)
KR (1) KR20110132590A (es)
CN (1) CN102348692A (es)
AR (1) AR075824A1 (es)
AU (1) AU2010223513B2 (es)
BR (1) BRPI1008939A2 (es)
CA (1) CA2755004A1 (es)
CL (1) CL2011002209A1 (es)
CO (1) CO6410292A2 (es)
EC (1) ECSP11011348A (es)
IL (1) IL214945A0 (es)
MX (1) MX2011009369A (es)
NZ (1) NZ595625A (es)
PE (1) PE20120790A1 (es)
RU (1) RU2011141188A (es)
TW (1) TWI461197B (es)
WO (1) WO2010102811A1 (es)
ZA (1) ZA201107444B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102778A2 (de) * 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
ES2537628T3 (es) 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3
CN103189357B (zh) 2010-08-27 2015-11-25 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
US8618129B2 (en) 2010-09-01 2013-12-31 Gruenenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
WO2014056620A1 (en) 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
WO2014082737A1 (en) * 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
EP2925759A1 (en) 2012-11-28 2015-10-07 Grünenthal GmbH Heteroquinoline-3-carboxamides as kcnq2/3 modulators
AU2014212426B8 (en) * 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
PH12015000236A1 (en) * 2015-07-06 2017-01-23 Samsung Electronics Co Ltd Electronic device for providing a calibrated keyboard configuration
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
DE102018212006B3 (de) 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
EP1147094A1 (en) * 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2001010381A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
WO2002072088A2 (en) * 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
US7087758B2 (en) * 2001-04-06 2006-08-08 Smithkline Beecham Corporation Quinoline inhibitors of hyaki and hyak3 kinases
EP1542966A1 (en) 2002-09-17 2005-06-22 Pharmacia Corporation Aromatic liver x-receptor modulators
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EA200601830A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
ME02970B (me) * 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
ATE432259T1 (de) 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
WO2008066900A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009019149A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (de) * 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators

Also Published As

Publication number Publication date
CN102348692A (zh) 2012-02-08
US20120252841A1 (en) 2012-10-04
CO6410292A2 (es) 2012-03-30
CA2755004A1 (en) 2010-09-16
AU2010223513A1 (en) 2011-11-03
WO2010102811A1 (de) 2010-09-16
IL214945A0 (en) 2011-11-30
TWI461197B (zh) 2014-11-21
PE20120790A1 (es) 2012-07-08
KR20110132590A (ko) 2011-12-08
ECSP11011348A (es) 2011-10-31
MX2011009369A (es) 2011-09-27
RU2011141188A (ru) 2013-04-20
JP5727946B2 (ja) 2015-06-03
US20100234372A1 (en) 2010-09-16
TW201034670A (en) 2010-10-01
BRPI1008939A2 (pt) 2016-03-15
AU2010223513B2 (en) 2014-12-04
AR075824A1 (es) 2011-04-27
JP2012520249A (ja) 2012-09-06
ZA201107444B (en) 2012-06-27
US8399673B2 (en) 2013-03-19
EP2406229A1 (de) 2012-01-18
NZ595625A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
CL2011002209A1 (es) Compuestos derivados de 2-mercaptoquinolin-3-carboxamida; medicamento que los comprende; y uso para tratar el dolor, epilepsia, incontinencia urinaria, ansiedad, dependencia manias, transtornos bipolares, migraña, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
BR112013021509A2 (pt) composições para cuidado pessoal
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
NI201600071A (es) Compuestos de inhibidor de autotaxina
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
SV2010003593A (es) Nuevos herbicidas
UY33199A (es) 5-alquinil-pirimidinas.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
PA8784301A1 (es) Oxazolidinonas sustituidas y su uso
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual